Proarrhythmia: Classification, Incidence, Risk Factors, Monitoring, Prevention and Management

Cardiac Electrophysiology Review

Volumn 2, Issue 2, 1998, Pages 127-131

  Grant, Augustus O ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0043035503     PISSN: 13852264     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009911212126     Document Type: Article

References (26)

1. Horowitz LN, Zipes DP, Bigger JT Jr, et al. Proarrhythmia, arrhythmogenesis or aggravation of arrhythmia - A status report. Am J Cardiol 1987;59:54E-56E.
2. The CAPS Investigators. The Cardiac Arrhythmia Pilot Study. Am J Cardiol 1986;57:91-95.
3. Wyse G, Morganroth J, Ledingham R, et al. New insights into the definition and meaning of proarrhythmia during initiation of antiarrhythmic drug therapy from the cardiac arrhythmia suppression trial and its pilot study. JACC 1994;23:1130-1140.
4. Skanes AC, Green MS. What have clinical trials taught us about proarrhythmia? Can J Cardiol 1996;12:20B-26B.
5. CAST Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. New Eng J Med 1989;321:406-412.
6. CAST-II. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. New Eng J Med 1992; 327:227-233.
7. CAPS Investigators. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: The CAPS. Am J Cardiol 1988;61:501-509.
8. Hohnloser SH. Proarrhythmia with class III antiarrhythmic drugs: Types, risks and management. Am J Cardiol 1997;80 (8A):82G-89G.
9. Lehmann MH, Timothy KW, Frankovich D, et al. Age-gender influence on the rate-corrected QT interval and the QT-heart rate relation in families with genotypically characterized long QT syndrome. JACC 1997;29:93-99.
10. Drici MD, Burklow TR, Haridasse V, Glazer RI, Woosley RL. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation 1996;94:1471-1474.
11. Roden DM, Woosley RL, Primm K. Oncidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care. Am Heart J 1986;111:1088-1093.
12. Bauman JL, Bauernfeind RA, Hoff JV, Strasberg B, Swiryn S, Rosen KM. Torsade de pointes due to quinidine: Observations in 31 patients. Am Heart J 1984;107:425-430.
13. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects: A review with special reference to torsade de pointes tachycardia. Ann Intern Med 1994;121:529-535.
14. Mattioni TA, Zhewtlin TA, Sarmiento JJ, Parker M, Lesch M, Kehoe RF. Amiodarone in patients with previous drug-mediated torsade de pointes. Ann Intern Med 1989;111:574-580.
15. MacNeil DJ. The side effect profile of class III antiarrhythmic drugs: Focus on d,l-sotalol. Am J Cardiol 1997;80(8A): 90G-98G.
16. Jackman WC, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long QT syndromes: A critical review, new clinical observations and unifying hypothesis. Prog in Cardiovasc Dis 1988;31:115-172.
17. Podrid PJ, Lampert S, Graboys TB, Blatt CM, Lown B. Aggravation of arrhythmia by antiarrhythmic drugs - Incidence and predictors. Am J Cardiol 1987;59:38E-44E.
18. Slater W, Lampert S, Podrid PJ, Lown B. Clinical predictors of arrhythmia worsening by antiarrhythmic drugs. Am J Cardiol 1988;61:349-353.
19. Botto GL, Bonini W, Broffoni T, et al. Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: Is in-hospital admission absolutely necessary? PACE 1996;19:1939-1943.
20. Maisel WH, Kuntz KM, Reimold SC, et al. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital. Ann Intern Med 1997;127:281-284.
21. Sihm I, Hansen FA, Rasmussen J, Pedersen AK, Thygesen K. Flecainide acetate in atrial flutter and fibrillation. Eur Heart J 1990;11:145-148.
22. Teo K, Yusuf S, Furberg C. Effect of antiarrhythmic drug therapy on mortality following myocardial infarction. Circulation 1990;82(4):III-197. (Abstract).
23. Ranger S, Talagic M, Lemery R, Roy D, Nattel S. Amplification of flecainide-induced ventricular conduction slowing by exercise. Circulation 1989;79:1000-1006.
24. Whitcomb DC, Gilliam FR, III, Starmer CF, Grant AO. Marked QRS complex abnormalities and sodium channel blockade by propoxyphene reversed with lidocaine. J Clin Invest 1989;84:1629-1643.
25. Morganroth J. Risk factors for the development of proarrhythmic events. Am J Cardiol 1987;59:32E-37E.
26. MacNeil DJ, Davies RO, Deitchman D. Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol 1993;72:44A-50A.